Transcept/Purdue’s Intermezzo Gets $29 Million Re-launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies will bulk up their sales force and begin a direct-to-consumer campaign in an effort to boost sales for their sleep aid, which has gotten off to a slow start since its launch in April.
You may also be interested in...
Deal Watch: Genentech Pays Big For Seragon’s Early Assets
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.
Transcept Gains Long-Delayed Approval Of Intermezzo
Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.